Algiax Reports Positive Phase 2a Study Results for AP-325 in Neuropathic Pain Patients

DÜSSELDORF, Germany I February 04, 2025 I - Algiax Pharmaceuticals, a biotech firm specializing in chronic neuropathic pain therapies, has reported promising results from its Phase 2a clinical trial for AP-325. This trial, centered on neuropathic pain treatment, highlighted AP-325's potential to rapidly alleviate pain and provide sustained benefits post-treatment. AP-325 is a non-opioid small molecule that targets GABA\(_A\) signaling to reduce pain. This chronic condition often results from imbalances in neuronal signaling, and AP-325 aims to address this by counteracting excessive neuron activation, potentially transforming pain management.

Dr. Ingo Lehrke, CEO of Algiax Pharmaceuticals, emphasized the importance of these findings, stating that they represent a crucial milestone in offering an effective, non-addictive treatment for patients with chronic neuropathic pain. He noted the company's commitment to expediting the availability of AP-325 to improve the lives of those suffering globally.

The Phase 2a study's key findings include promising clinical effects and a favorable safety profile, especially regarding central nervous system side effects commonly associated with standard treatments. Dr. Guido Koopmans, CSO of Algiax Pharmaceuticals, highlighted the pressing need for non-opioid treatments for chronic neuropathic pain, given the significant patient base worldwide. The results from this study suggest that AP-325 could significantly alter the landscape of pain management for these individuals.

Conducted as a randomized, double-blinded, placebo-controlled trial, the study assessed AP-325's safety and efficacy as a standalone treatment for peripheral post-surgical neuropathic pain. The trial involved 99 participants across 27 sites in Germany, Spain, the Czech Republic, Belgium, and France.

Algiax Pharmaceuticals is dedicated to developing enhanced, enduring solutions for neuropathic pain by modulating GABA\(_A\) signaling. AP-325, their leading small-molecule candidate, is undergoing Phase 2 evaluation and has already shown a strong safety profile and promising efficacy in early-stage trials. The company is also exploring GABA\(_A\) modulation further through its proprietary Thioacrylamide (ThAc) derivatives as potential follow-up treatments for neuropathic pain.